Our Mission

PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.

Click the orange button to the right to learn more.

Anti-Angiogenic Therapy for Pancreatic Cancer: What Patients Need to Know

Share Button

Anti-Angiogenic Therapy for Pancreatic Cancer: What Patients Need to Know. Can cutting off a tumor’s blood supply help treat pancreatic cancer?

The idea is called anti-angiogenic therapy. Angiogenesis is the process through which new blood vessels form. Because tumors need nutrients and oxygen to grow, researchers have spent decades investigating drugs and other compounds that interfere with the signals cancer uses to develop its blood supply.

But there is an important distinction for pancreatic cancer patients:

Anti-angiogenic therapy has shown meaningful clinical benefit for some pancreatic neuroendocrine tumors (pNETs), but anti-VEGF therapies have generally not improved overall survival in the much more common pancreatic ductal adenocarcinoma (PDAC).

I am a long-term survivor of an incurable blood cancer called multiple myeloma. My research and experience with evidence-based non-conventional therapies are the reason why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage aggressive cancers is to combine the best of conventional and evidence-based non-conventional therapies.

Scroll down the page and post a question or a comment if there’s anything you’d like to know about pancreatic cancer.

Good luck,

David Emerson


Concepts Central to Managing Your Cancer-


Possible Pancreatic Cancer Therapies:


Pancreatic Cancer Is Not One Disease

The term “pancreatic cancer” can refer to biologically different cancers.

Pancreatic ductal adenocarcinoma (PDAC) accounts for the great majority of pancreatic cancers and is the disease most people mean when they talk about pancreatic cancer.

Pancreatic neuroendocrine tumors (pNETs) develop from the pancreas’s hormone-producing neuroendocrine cells. They are much less common and can behave very differently from PDAC.

This matters because a treatment that works against a pancreatic neuroendocrine tumor should not automatically be assumed to work against pancreatic adenocarcinoma.


What Is Angiogenesis?

Cancer cells do not grow in isolation. As tumors enlarge, they interact with surrounding tissue and signaling pathways that can promote formation of new blood vessels.

One of the best-known signaling proteins involved is vascular endothelial growth factor (VEGF).

This led researchers to develop drugs designed to interfere with VEGF, VEGF receptors (VEGFR), and related pathways.

The biological idea makes sense: interfere with a tumor’s ability to develop or maintain its blood supply, and perhaps you can slow its growth.

Unfortunately, a biologically plausible cancer therapy does not always translate into improved survival in humans.

That is exactly what researchers have learned from pancreatic cancer.


Sunitinib and Pancreatic Neuroendocrine Tumors

Sunitinib (Sutent) is an oral targeted therapy known as a multitargeted tyrosine kinase inhibitor. Among other targets, it inhibits VEGF receptors and platelet-derived growth factor receptors (PDGFRs).

It is more accurate to call sunitinib a targeted therapy rather than chemotherapy.

An important randomized phase III trial enrolled 171 patients with advanced, well-differentiated pancreatic neuroendocrine tumors that had demonstrated disease progression.

Patients received either sunitinib or placebo.

The results were striking:

Outcome Sunitinib Placebo
Median progression-free survival 11.4 months 5.5 months
Objective response rate 9.3% 0%
Hazard ratio for progression or death 0.42 —

The trial was stopped early after investigators observed more serious events and deaths in the placebo group along with a substantial difference in progression-free survival.

Research: Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors – New England Journal of Medicine

Longer follow-up continued to support a substantial progression-free survival benefit. An independent review reported median progression-free survival of 12.6 months with sunitinib versus 5.8 months with placebo.

However, the later overall-survival analysis deserves more nuance. Median overall survival was 38.6 months versus 29.1 months, but the conventional intention-to-treat comparison was not statistically significant. Interpretation was complicated because many patients initially assigned to placebo later received sunitinib.

Research: Updated progression-free and overall survival with sunitinib in pancreatic neuroendocrine tumors – PubMed


PeopleBeatingCancer Evidence Rating

Therapy Setting Evidence PBC Rating
Sunitinib Progressive, well-differentiated pNET Randomized phase III clinical trial Strong
Anti-VEGF/VEGFR therapy Pancreatic ductal adenocarcinoma Multiple clinical trials/meta-analyses Evidence does not support routine use
Dietary/supplement anti-angiogenic compounds Pancreatic cancer Mostly laboratory/preclinical evidence Preliminary

The lesson is important: sunitinib’s success in pancreatic neuroendocrine tumors should not be generalized to ordinary pancreatic adenocarcinoma.


What About Anti-Angiogenic Therapy for Pancreatic Adenocarcinoma?

This is where the story becomes much less encouraging.

Laboratory research created considerable enthusiasm for targeting angiogenesis in pancreatic ductal adenocarcinoma. Pancreatic tumors can express VEGF and other factors involved in angiogenesis, and anti-angiogenic strategies produced encouraging results in preclinical models.

Human clinical trials, however, largely failed to reproduce those results.

A systematic review and meta-analysis examining therapies directed at the VEGF/VEGFR pathway found only marginal improvements in some measures such as response and progression-free survival and no improvement in overall survival.

Research: Therapies Targeting the Tumor Stroma and VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma – PubMed

Another systematic review examining clinical trials targeting the pancreatic tumor stroma analyzed anti-VEGF studies involving drugs such as:

  • bevacizumab
  • axitinib
  • sorafenib
  • aflibercept

The pooled results showed no overall-survival advantage from VEGF-targeting therapy.

Research: Clinical Trials Targeting the Stroma in Pancreatic Cancer – PubMed

That is an important example of why laboratory evidence and clinical evidence need to be separated.


Why Has Anti-Angiogenic Therapy Struggled in PDAC?

Pancreatic ductal adenocarcinoma has an unusually complex tumor microenvironment.

Unlike some highly vascular cancers, PDAC is often characterized by dense fibrotic tissue, abnormal vasculature, high interstitial pressure, immune suppression and a substantial stromal component surrounding the cancer cells.

In other words, pancreatic adenocarcinoma is not simply a tumor growing because it has too many blood vessels.

The interactions between:

  • cancer cells,
  • blood vessels,
  • fibroblasts,
  • immune cells,
  • extracellular matrix,
  • hypoxia and
  • molecular signaling pathways

make the tumor microenvironment extraordinarily difficult to target.

Researchers therefore continue to investigate approaches aimed at modifying the tumor microenvironment rather than simply “starving” pancreatic tumors of blood.

Research: Overview of Preclinical and Clinical Studies Targeting Angiogenesis in Pancreatic Ductal Adenocarcinoma – PubMed


What Treatments Are Used for Pancreatic Adenocarcinoma Today?

Treatment depends heavily on whether pancreatic cancer is:

  • resectable,
  • borderline resectable,
  • locally advanced or
  • metastatic.

Surgery offers the possibility of long-term disease control or cure for selected patients with resectable disease.

For advanced pancreatic adenocarcinoma, systemic treatment has evolved considerably since the research discussed in the original version of this article.

Current systemic approaches can include multi-drug regimens such as FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX, depending on disease stage, previous treatment, performance status, comorbidities and other patient-specific factors.

The National Cancer Institute summarizes current treatment options and the evidence supporting these regimens.

Research: Pancreatic Cancer Treatment – National Cancer Institute

This is another reason the original article needed updating: a study of sunitinib in a rare pancreatic neuroendocrine tumor should not be presented as evidence for treating pancreatic adenocarcinoma.


Could Nutrition or Supplements Influence Angiogenesis?

This is an interesting area of integrative oncology—but one where the strength of evidence needs to be stated carefully.

Laboratory and preclinical studies suggest that a number of food-derived compounds can affect molecular pathways associated with angiogenesis, inflammation, oxidative stress, cell proliferation, and apoptosis.

These include compounds found in:

  • turmeric/curcumin,
  • green tea/EGCG,
  • berries,
  • cruciferous vegetables,
  • grapes,
  • garlic,
  • tomatoes and
  • other plant foods.

But there is an important difference between showing that a compound affects VEGF signaling in a laboratory experiment and demonstrating that eating the food or taking a supplement improves survival in people with pancreatic cancer.

At present, anti-angiogenic foods or supplements should not be considered substitutes for evidence-based pancreatic cancer treatment.

They are better viewed as potential components of a broader nutrition and survivorship strategy, with supplement use discussed with the oncology team because supplements can sometimes interact with cancer drugs.


Related PeopleBeatingCancer Reading

If you’re just learning about pancreatic cancer, start here:

Pancreatic Cancer: Need to Know

PeopleBeatingCancer has explored several compounds being studied in the laboratory for their potential effects on pancreatic cancer biology.

Curcumin Enhances Pancreatic Cancer Chemotherapy

This article examines research suggesting that curcumin can influence proliferation, NF-kB signaling and angiogenesis and may interact with gemcitabine. Much of this evidence remains preclinical, so it should not be interpreted as proof of improved survival in pancreatic cancer patients.

Green Tea Polyphenol (EGCG) and Pancreatic Cancer

EGCG has demonstrated interesting biological effects in laboratory research. Again, laboratory activity should be distinguished from proven clinical benefit.

Pancreatic Cysts: To Treat or Not?

Pancreatic cysts present a different clinical problem, but some cystic lesions can carry malignant potential and require appropriate surveillance and risk assessment.


Questions to Ask Your Oncologist

If you have been diagnosed with pancreatic cancer, one of the first questions should be:

Exactly what type of pancreatic cancer do I have?

Other useful questions include:

  1. Is my diagnosis pancreatic ductal adenocarcinoma or a pancreatic neuroendocrine tumor?
  2. What is the stage and grade of my cancer?
  3. Is surgery possible?
  4. Should my tumor undergo molecular or genomic testing?
  5. Which systemic treatment options apply to my particular cancer?
  6. What benefits can I reasonably expect from treatment?
  7. What are the major short- and long-term side effects?
  8. Are there clinical trials appropriate for my diagnosis?
  9. Could any supplements I take interfere with treatment?
  10. Would consultation at a high-volume pancreatic cancer center be appropriate?

The Bottom Line

Anti-angiogenic therapy in pancreatic cancer illustrates an important principle of evidence-based oncology.

The biological theory can be compelling while the clinical results differ dramatically depending on the cancer subtype.

For pancreatic neuroendocrine tumors, targeting angiogenesis with sunitinib is supported by randomized clinical evidence and can significantly delay disease progression in appropriately selected patients.

For pancreatic ductal adenocarcinoma, however, anti-VEGF/VEGFR therapies have produced disappointing clinical results and have not demonstrated an overall-survival benefit sufficient to establish them as routine treatment.

Research into pancreatic cancer angiogenesis, tumor stroma and the tumor microenvironment remains important. But patients should distinguish carefully among laboratory evidence, clinical-trial evidence and treatments proven to benefit people with their particular pancreatic cancer subtype.

That distinction is especially important when considering supplements and other complementary therapies.


To learn more about the anti-cancer properties of angiogenesis, see the posts below-


To Learn More about Pancreatic Cancer:


Sunitinib (Sutent)

“Pancreatic neuroendocrine tumors– In November 2010, Sutent gained approval from the European Commission for the treatment of ‘unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in adults’.[9] In May 2011, the USFDA approved Sunitinib for treating patients with ‘progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic)’.[10]“

Drug May Help Fight Rare Pancreatic Cancer

A pill that cuts off the supply of nutrients to tumors shows promise for treating people with the rare type of pancreatic cancer that afflicted Apple CEO Steve Jobs.
 
In a study of 171 people with advanced pancreatic neuroendocrine tumors, the drug, Sutent, doubled the length of time before their disease worsened.
 
Cancer progressed in 5.5 months among patients on placebo vs. 11.4 months among patients on Sutent. Sutent also cut the risk of dying by 60%, says Eric Raymond, MD, head of medical oncology at the Hospital Beaujon in Clichy, France.
Anti-Angiogenic Therapy Pancreatic Cancer Anti-Angiogenic Therapy Pancreatic Cancer Anti-Angiogenic Therapy Pancreatic Cancer

Leave a Comment:

13 comments
C-B-D Myeloma- Anti-angiogenic - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Foods That Fight Myeloma- Angiogenesis Inhibitors - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Colorectal Cancer-Angiogenesis Inhibitors - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Anti-angiogenesis Extends Cervical Cancer Survival - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Metastatic Melanoma and Angiogenesis - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Myeloma Therapy- Antioxidants, Anti-inflammatory, Anti-Angiogenesis - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Angiogenesis, Starve Both Melanoma, Multiple Myeloma? - PeopleBeatingCancer says 3 years ago

[…] To Learn More about Angiogenesis and Cancer- click now […]

Reply
Neoadjuvant Therapy May Increase Resectability of Pancreatic Cancer - PeopleBeatingCancer says 7 years ago

[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Pancreatic Cancer Surgery-Biliary Drainage at Academic Center for Better Care? - PeopleBeatingCancer says 7 years ago

[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Pancreatic Cancer, Blue-Green Algae - PeopleBeatingCancer says 8 years ago

[…] Intravenous Vitamin C, Curcumin as Integrative Pancreatic Cancer Therapies Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Pancreatic Cysts-To Treat or Not? - PeopleBeatingCancer says 8 years ago

[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Experimental Biliary Cancer / Pancreatic Cancer Therapy - PeopleBeatingCancer says 8 years ago

[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Green Tea Polyphenol (EGCG) and Pancreatic Cancer. - PeopleBeatingCancer says 8 years ago

[…] Anti-Angiogenic Chemo May Help Fight Pancreatic Cancer […]

Reply
Add Your Reply